NEW ORLEANS, La.--()--2nd Opinion Stock Research has prepared a research report on Pristine Solutions, Inc (OTCQB: PRTN). Pristine Solutions, Inc is a developmental stage company pursuing new, patent pending therapies to treat hot flashes in menopausal women. In addition to a patent application, they plan to file a new use application with the FDA later this year. The candidate product is Tropine 3© which is an existing therapeutic product regulated by the FDA in anticholinergic applications.
To view the report in its entirety please click here:
2nd Opinion Stock Research is a small-cap equity research and financial public relations firm. 2nd Opinion Stock Research is not a FINRA member or registered broker/dealer. None of the profiles issued by 2nd Opinion Stock Research constitutes a recommendation for any investor to purchase or sell any particular security or that any security is suitable for any investor. Any investor should determine whether a particular security is suitable based on the investor’s objectives, other securities holdings, financial situation needs, and tax status. 2nd Opinion Stock Research expects to receive twenty thousand dollars from an unaffiliated third party for services rendered including preparation of this report and other investor relations services. This equity research report was prepared for informational purposes only. The analyst hereby certifies that he does not own any shares of the subject company.